Mutagenic Assessment of Olmesartan Cilexetil by Bacterial Mutation Assay.
- Author:
Ji Won KIM
1
;
Ilyoung AHN
;
Sung Ha RYU
;
Hong Ryeol JEON
;
Bong Sang LEE
;
Kyu Bong KIM
Author Information
1. Department of Pharmacology, CKD Research Institute, Yongin, Korea.
- Publication Type:Original Article
- Keywords:
Hypertension;
Olmesartan cilexetil;
Angiotension II receptor antagonist;
Mutagenicity
- MeSH:
Biotransformation;
Escherichia coli;
Hypertension;
Imidazoles;
Receptors, Angiotensin;
Salmonella typhimurium;
Tetrazoles
- From:Toxicological Research
2013;29(3):217-219
- CountryRepublic of Korea
- Language:English
-
Abstract:
Hypertension is a serious health problem due to high frequency and concomitant other diseases including cardiovascular and renal dysfunction. Olmesartan cilexetil is a new antihypertensive drug associated with angiotensin II receptor antagonist. This study was conducted to evaluate the mutagenicity of olmesartan cilexetil by bacterial reverse mutation test using Salmonella typhimurium (TA100, TA1535, TA98, and TA1537) and Escherichia coli (WP2 uvrA). At the concentrations of 0, 62, 185, 556, 1667, and 5000 microg/plate, olmesartan cilexetil was negative in both Salmonella typhimurium and Escherichia coli regardless of presence or absence of metabolic activation system (S9 mix). These results demonstrate that olmesartan cilexetil does not induce bacterial reverse mutation.
